-
公开(公告)号:US20250034521A1
公开(公告)日:2025-01-30
申请号:US18709406
申请日:2022-11-10
Applicant: Lupin Limited
Inventor: Sanjay Kumar Tiwari , Ankit Sharma , Snehit Shidhore
Abstract: The present invention relates to a process for producing a recombinant protein in a cell culture medium. comprising culturing mammalian cells expressing the protein of interest in a production medium at suitable conditions: and supplementing the production medium with feed components in such quantity that the residual carbon to nitrogen ratio is controlled. The present invention further relates to a process for producing a recombinant protein in a cell culture medium, wherein recombinant protein of interest has increased acidic variants and/or acidic variants and reduced basic variants.
-
公开(公告)号:US12124920B2
公开(公告)日:2024-10-22
申请号:US17768430
申请日:2020-10-03
Applicant: Lupin Limited
Inventor: Imran Shaikh , Mukul Dalvi , Xian-Ming Zeng , David Schaller , Cameron Alberg
CPC classification number: G06M1/248 , A61M15/0075 , A61M15/009 , G06M1/04 , G06M1/045 , G06M1/08 , G06M1/083 , A61M2016/0015 , A61M2205/3306 , A61M2205/3368 , A61M2205/3375 , A61M2205/583 , A61M2205/584
Abstract: Provided herein are new devices for indicating the status of events, such as the number of relevant events that are remaining and/or that have already occurred up to the present moment and to related devices, systems, and methods. In some aspects, the event-related indicator devices of the invention are used within larger dispensing devices or systems, e.g., to provide the status of administration of a substance contained therein (e.g., a drug). In an exemplary embodiment, the indicator devices find particular utility within medicament dispensers, such as metered dose inhalers, to provide a visual indication of the status of doses having been or remaining to be administered.
-
公开(公告)号:US20230049917A1
公开(公告)日:2023-02-16
申请号:US17789343
申请日:2020-12-26
Applicant: Lupin Limited
IPC: A61K31/5375 , A61K9/20 , A61K31/352 , A61K31/195 , A61K31/137 , A61P5/20
Abstract: The invention provides for a compound having the structure of Formula (I) to Formula (VI), including Compounds 1 to 6, their pharmaceutically acceptable salts, and compositions comprising thereof. This invention further includes methods of their use for the treatment of diseases or disorders associated with the modulation of calcium sensing receptors (CaSRs), including secondary hyperparathyroidism associated with chronic kidney disease in a subject in need thereof. This disclosure further relates to a process for the preparation of said pharmaceutical compositions.
-
公开(公告)号:US11278502B2
公开(公告)日:2022-03-22
申请号:US16146237
申请日:2018-09-28
Applicant: LUPIN LIMITED
Inventor: Shirishkumar Kulkarni , Satish Kumar Dalal , Harshal Jahagirdar , Kishore Kumar Konda
IPC: A61K9/50 , A61K47/38 , A61K31/165 , A61K9/20 , A61K47/32
Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
-
公开(公告)号:US10696636B2
公开(公告)日:2020-06-30
申请号:US16063732
申请日:2016-12-15
Applicant: Lupin Limited
Inventor: Girij Pal Singh , Dhananjai Shrivastava , Harishchandra Sambhaji Jadhav , Pramod Sudhakar Utekar , Digambar Yashwant Salunke
IPC: C07D213/803
Abstract: The present invention provides compound of formula (XVII), wherein P is hydroxyl protecting group; R2 and R3 are independently lower alkyl or R2 and R3 can be alkyl and joined to form a 5-, 6- or 7-membered ring; R4 is lower alkyl, and process for its preparation.
-
公开(公告)号:US10556069B2
公开(公告)日:2020-02-11
申请号:US15121430
申请日:2015-02-23
Applicant: LUPIN LIMITED
Inventor: Vishwajit Bhide , Raghuram Amperayani Pattabhi , Rohini Pimple , Bishu Choubey
IPC: A61M15/00
Abstract: An inhaler device comprising: a housing (2), a base plate (4) covering the housing (2), a medicament holder (10) integrated with the base plate (4), a mouthpiece (3) sitting over the base plate (4), a lid (1) which covers the mouthpiece (3), at least one piercing element (11), an actuating member (5), a spring (12), and is characterized in that the inhaler device is a two hinges system (6,8) wherein the base plate (4) is joined to hinge (6); the mouthpiece (3) and the lid (1) are joined to the hinge (8).
-
公开(公告)号:US20190275012A9
公开(公告)日:2019-09-12
申请号:US16320902
申请日:2017-07-28
Applicant: Lupin Limited
Inventor: Gagan Kukreja , Nageswara Rao Irlapati , Arun Rangnath Jagdale , Gokul Keruji Deshmukh , Vinod Popatrao Vyavahare , Kiran Chandrashekhar Kulkarni , Neelima Sinha , Venkata P. Palle , Rajender Kumar Kamboj
IPC: A61K31/429 , A61P35/02 , A61P37/00 , A61P11/00
Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.
-
公开(公告)号:US20190256498A1
公开(公告)日:2019-08-22
申请号:US16316213
申请日:2017-07-07
Applicant: LUPIN LIMITED
Inventor: Palash SANPHUI , Radhakrishna Bhikaji SHIVDAVKAR , Gurvinder Pal SINGH , Purna Chandra RAY , Girij Pal SINGH , Vikas Ashokrao SADAPHAL , Lalitkumar Dilipising RAJPUT , Hemraj Mahadeorao LANDE
IPC: C07D403/14
Abstract: The present invention provides novel crystalline form L1 of daclatasvir dihydrochloride wherein the diffraction peaks at 5.35, 6.04, 6.76, 8.65, 9.21, 10.35, 10.32, 10.75, 11.04, 11.66, 12.95, 13.56, 16.06, 18.11, 20.58, 22.18, 23.27±0.2 degree two theta in an X-ray diffraction pattern. The present invention provides novel crystalline form L2 of daclatasvir dihydrochloride wherein the diffraction peaks at 8.27, 9.54, 11.06, 13.61, 15.34, 19.01, 22.26, 23.24, 24.73, 25.35±0.2 degree two theta in an X-ray diffraction pattern. The present invention further provides process for preparation of crystalline forms L1 and L2 of daclatasvir dihydrochloride.
-
公开(公告)号:US10377712B2
公开(公告)日:2019-08-13
申请号:US15577102
申请日:2016-05-26
Applicant: LUPIN LIMITED
Inventor: Palash Sanphui , Ananda Pundlik Sapdhare , Arunkumar Digambar Patil , Hemraj Mahadeorao Lande , Gurvinder Pal Singh , Puma Chandra Ray , Nandu Baban Bhise , Girij Pal Singh , Mithun Dasharath Surwase , Shantanu Gokuldas Varade , Govind Dnyanoba Ausekar , Radhakrishna Bhikaji Shivdavkar
IPC: C07D209/48 , C07C315/04
Abstract: The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. This invention also provides novel polymorphs of apremilast. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale.
-
公开(公告)号:US20190135803A1
公开(公告)日:2019-05-09
申请号:US16095424
申请日:2017-04-12
Applicant: LUPIN LIMITED
Inventor: Tushar Nandkumar DESPANDE , Dnyaneshwar Tukaram SINGARE , Yogesh Dadaji PAWAR , Yuvraj Atmaram CHAVAN , Purna Chandra RAY , Girij Pal SINGH
IPC: C07D455/06
CPC classification number: C07D455/06 , C07B2200/05
Abstract: The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) and further converting it to tetrabenazine (I) and deutetrabenazine (II).
-
-
-
-
-
-
-
-
-